Clinipace

What Clinipace does

Clinipace is a privately held, US-based Contract Research Organization (CRO) founded in 2003 and headquartered in Morrisville, North Carolina. The firm provides integrated clinical research services to biopharmaceutical and medical device sponsors, delivering end-to-end support across the clinical development lifecycle. Its service portfolio spans 12 therapeutic areas (including Oncology & Hematology, Rare Disease, Cell & Gene Therapy, Neurology, Immunology, Cardiovascular-Metabolic, and Pediatrics) and covers Early Phase Development, Phase II/III, Regulatory Strategy, Medical Affairs, Post-Marketing Solutions, and operational services such as Clinical Operations, Study Start-Up, RBQM, Biometrics, Medical Writing, Pharmacovigilance, and Quality Assurance. The company has scaled to 800+ employees through a combination of organic growth and six disclosed acquisitions between 2009 and 2015 (Worldwide Clinical Research, Regulus, PFC Pharma Focus, Paragon Biomedical, Choice Pharma, and Accovion) that extended its reach into Europe and Asia-Pacific.

The business is funded primarily through private equity and growth equity rather than public capital markets. Clinipace has raised approximately $182M+ across 14 disclosed funding rounds between 2005 and 2021, anchored by repeat participation from Hatteras Venture Partners, Harbert Growth Partners, Morgan Stanley Expansion Capital, and Crestline, with the most recent $50M Series 3 closed in July 2021 led by SpringHill Management. Leadership includes Chairman/CEO Lingshi Tan, Chairman of the Board Kenneth Lee, CFO Karen D Turner, and Chief Development Officer Dawn Sauro; long-time co-founder Christopher K. Porter served as President, COO, and General Counsel before departing in 2026.

The company operates in a global CRO market valued at $64.11B in 2024 and projected to reach $119.85B by 2033, competing within a North American region that represents 51% of CRO market share in 2025. Source materials indicate the firm now operates under the "Caidya" brand, with Caidya listed as previously known as Clinipace Worldwide, suggesting a corporate rebrand. The firm's current monetization mechanics — pricing, contract structure, customer mix, and deal economics — are not disclosed in the available source data.

Name

Clinipace

Legal name

Caidya

Website

https://clinipace.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Clinipace is a US-based clinical research organization providing integrated CRO services across 12 therapeutic areas and the full clinical development lifecycle to biopharmaceutical and medical device sponsors, with 800+ employees and global operations.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial management
• Biopharmaceutical development
• Medical device research

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Core offering

Clinipace is a Contract Research Organization (CRO) providing outsourced clinical trial execution and clinical development services to biopharmaceutical and medical device companies. Its offerings span 12 therapeutic-area specialties (Oncology & Hematology, Rare Disease, Cell & Gene Therapy, Neurology, Immunology, Infectious Disease, Pediatrics, and others) and the full clinical development lifecycle from Phase I through post-marketing, including clinical operations, regulatory strategy, biometrics, data management, pharmacovigilance, and quality assurance.

Product overview

Caidya (the available source data company) is a clinical research organization (CRO) offering a unified platform of clinical development services. The portfolio consists of therapeutic expertise across 12 specialty areas (Oncology & Hematology, Rare Disease, Cardiovascular-Metabolic, Pediatrics, Gastroenterology, Nephrology, Dermatology, Ophthalmology, Cell & Gene Therapy, Neurology, Immunology, and Infectious Disease) paired with clinical development strategy services (Early Phase Development, Phase II/III, Regulatory Strategy, Medical Affairs, Post-Marketing Solutions) and clinical trial delivery services (Clinical Operations, Study Start-Up, Trial Feasibility, Project Management, RBQM, Medical Monitoring, Clinical Data Management, Biometrics, Medical Writing, Regulatory Services, Pharmacovigilance, Quality Assurance, Service Models). The company positions itself as a flexible CRO combining scientific, medical, and operational expertise with a flat structure and cross-border trial capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology & Hematology Specialized development services for oncology and hematology, designed to handle complexity with precision and agility across every trial phase. Targeted at biopharmaceutical sponsors in oncology and hematology.
• Cardiovascular-Metabolic Development expertise for cardiovascular and metabolic disorders. Targeted at sponsors running clinical trials in cardiovascular-metabolic indications.
• Rare Disease Patient-first design, global reach, and tailored execution for rare disease trials addressing small patient populations and fragmented care. Targeted at biopharma sponsors developing therapies for rare diseases.
• Pediatrics Clinical development services tailored for pediatric populations. Targeted at sponsors running pediatric clinical trials.
• Cell & Gene Therapy Specialized development expertise for cell and gene therapy approaches. Targeted at sponsors advancing cell and gene therapy programs.
• Neurology Development expertise for neurological disorders. Targeted at sponsors running trials in neurology indications.
• Early Phase Development Phase I and early phase clinical trial development services. Targeted at sponsors requiring Phase I execution and first-in-human studies.
• Phase II/III Mid-to-late stage clinical trial execution services. Targeted at sponsors advancing pivotal Phase II and Phase III studies.
• Regulatory Strategy Regulatory affairs planning and strategy services. Targeted at sponsors needing regulatory pathway design and agency interaction support.
• Post-Marketing Solutions Services for post-marketing surveillance and studies. Targeted at sponsors needing late-phase real-world evidence generation.
• Clinical Operations Core operational execution of clinical trials. Targeted at sponsors requiring outsourced trial management.
• Clinical Data Management Data management and database services for clinical trials. Targeted at sponsors needing clinical data capture and cleaning.
• Biometrics Biostatistics and statistical programming services for clinical trials. Targeted at sponsors needing statistical analysis and programming support.
• Pharmacovigilance Drug safety and pharmacovigilance services. Targeted at sponsors requiring adverse-event monitoring and safety reporting.
• Quality Assurance Quality assurance and audit services for clinical trial compliance. Targeted at sponsors needing GCP/GLP audit and quality oversight.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Charles River Laboratories: Charles River provides preclinical and clinical services with strong cell & gene therapy and biologics capabilities, directly comparable to Caidya's emphasis on cell & gene therapy and specialty therapeutics.
• Medpace: Medpace is a mid-to-large full-service CRO with therapeutic specialization and global trial execution capabilities that closely mirror Caidya's model, making it the most directly comparable peer for a mid-sized, scientifically-led CRO.
• Syneos Health: Syneos Health is a full-service biopharmaceutical services organization offering clinical and commercial solutions; comparable in scale and service breadth to Caidya with similar global CRO positioning.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized, scientifically-led CRO with strong therapeutic specialization in areas like neuroscience and rare disease, comparable to Caidya's specialty-led positioning and mid-market scale.

Broad incumbents

• IQVIA: IQVIA is the largest global CRO and life-sciences technology firm, offering the full spectrum of clinical development, data, and commercial services that overlap directly with Caidya's therapeutic and operational portfolio.
• ICON plc: ICON is one of the world's largest CROs with broad therapeutic and operational coverage spanning early through post-marketing, competing with Caidya on full-service Phase I–IV trials and biometrics.
• Parexel International: Parexel is a large global CRO with deep therapeutic expertise (notably in oncology and rare disease) and full clinical-to-commercial service offerings, directly overlapping Caidya's specialty franchise positioning.
• Labcorp Drug Development (formerly Covance): Labcorp Drug Development is the clinical development arm of Labcorp, offering early-to-late phase CRO services plus central laboratory and diagnostics, overlapping with Caidya's Phase I–IV and data/biometrics capabilities.

Emerging players

• Wuxi AppTec: Wuxi AppTec is a leading global CRO/CDMO with strong Asia-Pacific presence and full-service clinical development capabilities, comparable to Caidya in service breadth and geographic reach, especially as Asia-Pacific grows fastest.
• Pharmaron: Pharmaron is a global CRO/CDMO offering integrated drug discovery, preclinical, and clinical services with strong China-based operations; comparable to Caidya in offering end-to-end development including biologics and cell/gene therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Caidya
• LinkedInlinkedin.com/company/caidya
• Instagraminstagram.com/weare_caidya
• Xx.com/clinipace

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds14 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinipace